CSF2 and ovarian carcinoma: We have completed a prospective phase I/IIa trial of E39 + granulocyte macrophage‐colony stimulating factor (GM‐CSF) to prevent recurrence in endometrial and ovarian cancer patients at high risk for recurrence after being rendered disease‐free by standard of care therapy.